[go: up one dir, main page]

ME03653B - Postupci za dobijanje indazol derivata - Google Patents

Postupci za dobijanje indazol derivata

Info

Publication number
ME03653B
ME03653B MEP-2019-326A MEP2019326A ME03653B ME 03653 B ME03653 B ME 03653B ME P2019326 A MEP2019326 A ME P2019326A ME 03653 B ME03653 B ME 03653B
Authority
ME
Montenegro
Prior art keywords
processes
manufacturing
indazole derivatives
indazole
derivatives
Prior art date
Application number
MEP-2019-326A
Other languages
German (de)
English (en)
French (fr)
Inventor
Robert Nicholas Bream
John David Hayler
Alan Geoffrey Ironmonger
Peter Szeto
Michael Robert Webb
Katherine Marie Penelope Wheelhouse
Robert David Willacy
Original Assignee
Glaxosmithkline Ip Dev Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxosmithkline Ip Dev Ltd filed Critical Glaxosmithkline Ip Dev Ltd
Publication of ME03653B publication Critical patent/ME03653B/me

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D413/00Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4151,2-Diazoles
    • A61K31/4161,2-Diazoles condensed with carbocyclic ring systems, e.g. indazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42Oxazoles
    • A61K31/422Oxazoles not condensed and containing further heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/32Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F5/00Compounds containing elements of Groups 3 or 13 of the Periodic Table
    • C07F5/02Boron compounds
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Catalysts (AREA)
MEP-2019-326A 2015-06-02 2016-05-31 Postupci za dobijanje indazol derivata ME03653B (me)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1509492.3A GB201509492D0 (en) 2015-06-02 2015-06-02 Novel processes
PCT/EP2016/062250 WO2016193255A1 (en) 2015-06-02 2016-05-31 Processes to make indazole derivatives
EP16726309.4A EP3303329B1 (en) 2015-06-02 2016-05-31 Processes to make indazole derivatives

Publications (1)

Publication Number Publication Date
ME03653B true ME03653B (me) 2020-07-20

Family

ID=53677608

Family Applications (1)

Application Number Title Priority Date Filing Date
MEP-2019-326A ME03653B (me) 2015-06-02 2016-05-31 Postupci za dobijanje indazol derivata

Country Status (22)

Country Link
US (1) US10266525B2 (me)
EP (1) EP3303329B1 (me)
JP (1) JP6389967B2 (me)
KR (1) KR20180011115A (me)
CN (1) CN107660204B (me)
AU (1) AU2016273752B2 (me)
BR (1) BR112017023486B1 (me)
CA (1) CA2983966A1 (me)
CY (1) CY1122343T1 (me)
DK (1) DK3303329T3 (me)
ES (1) ES2760571T3 (me)
GB (1) GB201509492D0 (me)
HR (1) HRP20192117T1 (me)
HU (1) HUE047523T2 (me)
ME (1) ME03653B (me)
PL (1) PL3303329T3 (me)
PT (1) PT3303329T (me)
RS (1) RS59639B1 (me)
RU (1) RU2017134467A (me)
SI (1) SI3303329T1 (me)
SM (1) SMT201900705T1 (me)
WO (1) WO2016193255A1 (me)

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO3025B1 (ar) * 2009-04-30 2016-09-05 Glaxo Group Ltd الأندازولات المستبدلة بالأوكسازول كمثبطات كيناز pi3
JP5876051B2 (ja) * 2010-09-08 2016-03-02 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドGlaxosmithkline Intellectual Property Development Limited インフルエンザウィルス感染の治療に使用するためのインダゾール誘導体
EP2614058B1 (en) * 2010-09-08 2015-07-08 GlaxoSmithKline Intellectual Property Development Limited POLYMORPHS AND SALTS OF N-[5-[4-(5-{[(2R,6S)-2,6-DIMETHYL-4-MORPHOLINYL]METHYL}-& xA;1,3-OXAZOL-2-YL)-1H-INDAZOL-6-YL]-2-(METHYLOXY)-3-PYRIDINYL]METHANESULFONAMIDE
GB201018124D0 (en) * 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
US20160263109A1 (en) * 2013-10-17 2016-09-15 Glaxosmithkline Intellectual Property Development Limited P13k inhibitor for treatment of respiratory disease

Also Published As

Publication number Publication date
AU2016273752A1 (en) 2017-10-19
CY1122343T1 (el) 2021-01-27
HUE047523T2 (hu) 2020-04-28
RU2017134467A (ru) 2019-07-15
DK3303329T3 (da) 2019-12-02
BR112017023486B1 (pt) 2023-02-14
AU2016273752B2 (en) 2018-07-05
GB201509492D0 (en) 2015-07-15
EP3303329B1 (en) 2019-09-18
US20180155334A1 (en) 2018-06-07
CN107660204B (zh) 2021-04-13
RS59639B1 (sr) 2020-01-31
KR20180011115A (ko) 2018-01-31
ES2760571T3 (es) 2020-05-14
BR112017023486A2 (pt) 2018-07-24
PL3303329T3 (pl) 2020-03-31
JP2018518477A (ja) 2018-07-12
US10266525B2 (en) 2019-04-23
HRP20192117T1 (hr) 2020-02-21
WO2016193255A1 (en) 2016-12-08
CA2983966A1 (en) 2016-12-08
CN107660204A (zh) 2018-02-02
EP3303329A1 (en) 2018-04-11
PT3303329T (pt) 2019-12-16
SI3303329T1 (sl) 2020-02-28
JP6389967B2 (ja) 2018-09-12
RU2017134467A3 (me) 2019-10-11
SMT201900705T1 (it) 2020-01-14

Similar Documents

Publication Publication Date Title
EP3579833A4 (en) Methods of treating influenza
EP3347458A4 (en) MULTI TRANSGENIC PIG FOR XENOTRANSPLANTATION
EP3324840A4 (en) MEASURING TEST STRIPS FOR FLOW ESTIMATION
SI3097098T1 (sl) Postopek za pripravo N-((3-aminooksetana-3-il)metil)-2-(1,1-diokso- 3,5-dihidro-1,4-benzotiazepin-4-il)-6-metil-kinazolin-4-amina
MA46652A (fr) Polythérapie pour l'inhibition de c3
MA41140A (fr) Dérivés de 2,4-dioxo-quinazoline-6-sulfonamide en tant qu'inhibiteurs de la parg
EP3353278A4 (en) SPECIMEN PREPARATION FOR HEAVY SPECIMENS
EP3313381A4 (en) BIOMARKERS FOR NANOPARTICLE COMPOSITIONS
EP3630078A4 (en) CHEMOEMBOLIZING AGENTS
MA55193A (fr) Procédés de préparation d'un inhibiteur de pi3k
EP3420598A4 (en) METHOD FOR PRODUCING PEROVSKIT HALID FILMS
EP3519028A4 (en) JOCH FOR HEADGEAR
EP3310439A4 (en) PHARMACEUTICAL COMPOSITIONS FOR ANESTHESIOLOGICAL APPLICATIONS
EP3398957A4 (en) PROCESS FOR SYNTHESIS OF ETELCALCETIDE
MA41203A (fr) Procédés pour la préparation d'un composé diaryl-thiohydantoïne
EP3375432A4 (en) COMPOSITION FOR THE MOUTH CAVE
EP3408731A4 (en) INTERACTION MODES FOR OBJECT DEVICE INTERACTIONS
EP3400300A4 (en) PROCESS FOR REDUCING LRRK2 EXPRESSION
EP3378585A4 (en) BINDING COMPOSITION
MA45373A (fr) Composition pour agent extincteur
EP3405864A4 (en) SPOOFING CPUID FOR DOWNWARD COMPATIBILITY
EP3312172A4 (en) aminopyrazole
EP3506748A4 (en) IMPROVED METHOD OF PERMETHRIN SYNTHESIS
MA42048A (fr) Dérivés d'aminoesters
EP3324993A4 (en) COMPOSITION FOR THE TREATMENT OF RSV